Multimodality treatment is an accepted standard for optimal management of patients with locally advanced non-small cell lung cancer (NSCLC). In particular, induction chemotherapy followed by combined radiochemotherapy and/or surgical resection is highly effective and potentially curative in selected stage III patients ([@bib14]; [@bib22]). Definitive radiochemotherapy after induction chemotherapy is a recommended treatment strategy for locally advanced, inoperable stage IIIA/B NSCLC patients ([@bib1]). Tubulin-binding agents (TBAs) such as taxanes and *Vinca* alkaloids act by impairing the normal function of mitotic spindles. Microtubules are composed of *αβ*-dimers and form the fibres of the mitotic spindle. TBAs target microtubules and change their polymerisation or depolymerisation dynamics, ultimately leading to mitotic arrest and cell death ([@bib18]). Paclitaxel binds to *β*-tubulin that leads to tubulin polymerisation, microtubule stabilisation ([@bib27]), and inhibition of microtubule disassembly in cancer cells ([@bib19]).

The eight members of the *β*-tubulin gene family produce homologous proteins that differ most notably in the last 15--20 C-terminal amino acids ([@bib3]; [@bib5]). These carboxyl-terminal sequences have been used to assign *β*-tubulin gene products to eight distinct classes. Each of these classes (referred to as *β*I, *β*II, *β*III, *β*IVa, *β*IVb, *β*V, *β*VI, and *β*VII) defines a *β*-tubulin isotype that differs significantly from other isotypes within the same organism, but is highly conserved between other vertebrate species ([@bib4]). Murine and human *β*III- or *β*V-tubulin display 99.8 or 97.7% sequence identity and human *β*V-tubulin differs mainly at the last two C-terminal amino-acid residues from the corresponding rodent residues ([@bib33]).

Disregarding *β*VI- and *β*VII-tubulin, *β*-tubulin isotypes fall into two distinct evolutionary branches consisting of *β*I-, *β*II-, and *β*IV-tubulin on the one hand, and *β*III- and *β*V-tubulin on the other ([@bib33]). One striking difference between the tubulin isotypes *β*III and *β*V is that the latter is found in glia and not in neurons (except some ganglion cells), whereas *β*III-tubulin is found in neurons and not in glia ([@bib32]; [@bib33]). Both of these isotypes are expressed in cancer cells, although their patterns of expression seem to be reciprocal (low *β*III-tubulin/high *β*V-tubulin and vice versa) ([@bib33]; [@bib16]). Recently, *β*V-tubulin expression was found to predict poor outcome in colorectal cancer patients and gender might influence the predictive value of *β*III-/*β*V-tubulin expression ([@bib25]).

Overexpression of *β*III-tubulin moderately destabilised microtubules in cells that were weakly paclitaxel resistant ([@bib15]), and reduced the ability of paclitaxel to suppress microtubule dynamics ([@bib20]). *β*III-tubulin expression in cancer cells or primary tumours was correlated with a decreased sensitivity to paclitaxel ([@bib27]). Several studies reported a correlation between low or absent intratumoural *β*III-tubulin expression and improved objective response (OR) ([@bib30]; [@bib35]), as well as prolonged progression-free survival (PFS) ([@bib10]; [@bib30]; [@bib35]; [@bib2]) in paclitaxel-treated patients with locally advanced or metastatic NSCLC. However, contradictory results have also been reported ([@bib29]; [@bib1]; [@bib21]). Equally contradictory reports have been published regarding the association of *β*III-tubulin expression with overall survival (OS) ([@bib10]; [@bib30]; [@bib26]; [@bib1], [@bib2]; [@bib21]; [@bib35]). In contrast, *β*V-tubulin has received less attention despite its similarity to *β*III-tubulin, which also suggests a possible interaction with TBAs ([@bib3]).

We hypothesised that combined analysis of *β*III- and *β*V-tubulin protein expression may result in an improved predictive biomarker for NSCLC patients undergoing taxane-based chemotherapy. At the initiation of this study there was no anti-human *β*V-tubulin antibody available, which was tested for immunohistochemistry (IHC). Therefore, we established and validated a *β*V-tubulin assay.

Materials and methods
=====================

Patients
--------

This retrospective study examined pre-treatment tumour samples from 65 patients treated at a single comprehensive cancer centre (West German Cancer Centre, University Hospital Essen, Essen, Germany), who were diagnosed between July 2003 and January 2010. Paclitaxel-based induction treatment was initiated between May 2004 and January 2010. Locally advanced NSCLC patients with histopathologically (by bronchoscopy and mediastinoscopy) proven stage IIIA (N2), and selected patients with stage IIIB or oligometastatic stage IV (single metastasis, e.g., in adrenal glands) were included. None of the patients had received prior chemotherapy. Detailed clinicopathological and epidemiological characteristics [(Table 1](#tbl1){ref-type="table"}) were obtained via chart review conducted by an independent investigator, who was blinded to the results of the immunohistochemical analysis. Clinical and pathological tumour stages were classified according to the seventh edition of the tumour-node-metastasis system, which is recommended by the International Association for the Study of Lung Cancer (IASLC) ([@bib9]). Tumour histology was classified based on World Health Organisation criteria. Analysis of tumour samples and clinical data was consented by all alive patients; the study was approved by the Ethics Committee of the Medical Faculty of the University Duisburg-Essen (no. 10-4404).

Treatment
---------

Patients received ([Figure 1](#fig1){ref-type="fig"}: flowchart of patients\' treatment) induction chemotherapy (CTX) followed by radiochemotherapy consisting of hyperfractionated radiotherapy and chemotherapy. If technically and functionally feasible and restaging showed no progression, patients underwent surgery 3--5 weeks after the end of radiochemotherapy. In patients deemed inoperable at the end of radiochemotherapy or with comorbidities excluding operation, a definitive boost of radiochemotherapy was added. This therapy was in accordance to accelerated radiotherapy reports with a final boost and concomitant chemotherapy ([@bib28]).

Treatment evaluation
--------------------

Tumour response was evaluated separately following induction chemotherapy and radiochemotherapy. Patients received computed tomography (CT) scans of the chest and upper abdomen, bone scans, or in the majority of cases whole-body positron emission tomography--CT scans, and brain imaging (magnetic resonance imaging in the majority of cases) before induction chemotherapy and CT-scans at least every 6 weeks during treatment following standard procedures. Response to chemotherapy and radiochemotherapy was quantified according to RECIST (Response Evaluation Criteria in Solid Tumours) version 1.1 ([@bib11]).

Establishment and validation of a *β*V-tubulin assay
----------------------------------------------------

### Transfections

Hemagglutinine (HA)-tagged *β*I-/*β*III-/*β*V-tubulin cDNAs subcloned into pTOPneo expression plasmids under the control of a CMV promoter were kindly provided by Fernando R. Cabral (Department of Integrative Biology and Pharmacology, The University of Texas Medical School, Houston, TX, USA): pTOP HAbI (6663 bp; GenBank accession no. U08342.1), pTOP HAbIII (6583 bp; GenBank accession no. BC031357.1), and pTOP HAbV (7007 bp; GenBank accession no. BC008225 ([@bib8]; [@bib4]). HEK293T cells were obtained from the German Collection of Microorganisms and Cell Cultures and were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS, Coelbe, Germany), ℒ-glutamine, penicillin and streptomycin (Invitrogen, Darmstadt, Germany) at 37 °C, in a 5% CO~2~-humidified incubator. Transient expression of *β*-tubulin isoforms was achieved by standard calcium phosphate transfection as described previously ([@bib23]). Transfection efficacies were estimated by parallel transfection of the plasmid pLPC-EGFP and visualisation of green fluorescent cells by microscopy ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}).

### Protein extract preparation and immunoblotting

Protein lysates were prepared 48 h after transfection using a NP-40 containing lysis buffer as described previously ([@bib17]). Immunoblotting with an anti-HA primary antibody (mouse mAb, clone 12CA5, Roche Diagnostics, Mannheim, Germany) was performed as described previously ([@bib23]).

### Immunocytochemistry/IHC of transgenic control cells and primary tumour biopsies

HEK293T cells transfected to express the *β*-tubulin isotypes I, III, and V were grown in cell culture plates until sub-confluency and harvested. A cell pellet was prepared by centrifugation, washed twice with phosphate-buffered saline (PBS, Mediatech, Manassas, VA, USA), resolved in fixating solution consisting of 50% ethanol and 50% of PBS (10%)-buffered formalin, and fixed for a minimum of 6 h. After fixation, the pellet was collected by centrifugation, processed, and embedded in paraffin. The resulting blocks were sectioned at 5 μm thickness and mounted on Plus GOLD slides (Fisher Scientific, Schwerte, Germany).

Sections of formalin-fixed paraffin-embedded blocks of NSCLC tumour samples and transgenic control cell pellets were deparaffinised in xylene, dehydrated in a graded ethanol series, and incubated with blocking solution (Peroxid Block, Zytomed Systems, Berlin, Germany). Antigens were retrieved by heating samples in sodium citrate buffer, pH 6.0, for 20 min, and the following primary antibodies were used ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}): anti-HA antibody (mouse mAb, clone 6E2, Cell Signaling Technology, Danvers, MA, USA), anti-*β*III-tubulin (mouse mAb, clone TU-20, Zytomed Systems), and anti-*β*V-tubulin (mouse mAb, clone 87CT59.3.7, Abgent, San Diego, CA, USA). Specific staining was detected using horseradish peroxidase (HRP)-labelled rabbit anti-mouse antibody (ZytoChemPlus (HRP) Polymer Kit, Zytomed Systems) and a 3,3′-diaminbenzidine (DAB) substrate system (DAB Substrate Kit, Zytomed Systems). Slides were counterstained with hematoxylin. Negative controls were performed by omitting the primary antibody. Furthermore, we used a brain metastasis containing a regular cortex with both neurons and glia cells, which was resected from a patient with a squamous cell carcinoma of the lung, for another set of positive and negative controls ([Supplementary Figures 3A--C](#sup1){ref-type="supplementary-material"}). Non-small cell lung cancer resection specimens having pleural nerves or nerve fascicles served as internal positive controls ([Supplementary Figures 3D--F](#sup1){ref-type="supplementary-material"}).

Immunohistochemistry evaluations were performed independently by one pathologist (JW) and one trained reader (DCC) who were blinded to the clinical data. Cytoplasmic immunoreactivity levels in each section were assessed under a light microscope and images were captured at 400-fold magnification. Tumour staining intensity was graded on a scale from 0+ to 3+ and each intensity category was scored a percentage of tumour cells ranging from 0 to 100 so that the sum of the percentages adds up to 100. The percentage score was then multiplied by its intensity category to obtain a final '*H*-score\', ranging from 0 to 300. Ambiguous cases were reevaluated jointly until a consensus was reached.

Statistical methods
-------------------

The objective of this study was to assess the association of two selected biomarkers (*β*III- and *β*V-tubulin) with treatment response and outcome of patients with locally advanced or oligometastatic NSCLC. For metric variables, such as age and biomarker expression scores, Spearman\'s rank correlation coefficients were computed ([@bib31]). Associations between biomarker expression scores and patients\' clinicopathological data were assessed using the Kruskal--Wallis test or Wilcoxon ranked sum test (test is equivalent to Kruskal--Wallis test when comparing two groups). For efficacy analyses, the population was divided into two groups according to median *H*-score value of the respective marker and this cutoff value was *a priori* chosen.

The accuracy of *β*III- and *β*V-tubulin protein levels to distinguish between patients with response and non-response to paclitaxel-based treatment was evaluated by means of descriptive statistics and receiver operating characteristics (ROC) curves ([@bib12]). When a significant *P*-value was found, ROC curves were computed to find an adequate threshold value for which the trade-off among sensitivity and specificity was acceptable.

PFS was calculated from the first day of induction chemotherapy until progression or the last visit when a patient was alive without progression. Overall survival was defined as the time between the start of chemotherapy until the date of death, or last follow-up. Patients were censored at last follow-up if still alive or lost to follow-up. Surveillance of PFS and OS was stopped on 15 August of 2011. Survival analysis was performed by calculating Kaplan--Meier curves and the significance was verified by log-rank tests. Univariate and multivariate analyses of survival were carried out using the Cox proportional hazard model, with hazard ratios (HRs) with 95% confidence interval (CI) being calculated alongside. Decrements or increments of 30 units of the *H*-score (which refer to changes in the *H*-score of units of 10%) were used when *β*-tubulin levels were included as continuous variables in the Cox regression model ([@bib24]). Cox regression analysis neither included stage nor surgical procedure because of low patient numbers (40 patients underwent resection). The level of significance was set at *α*=0.05 for each evaluation. Nevertheless, as this is a retrospective study all *P*-values or results of statistical tests should be regarded as exploratory. All analyses were performed using GraphPad Prism (Version 5.00 for Windows, GraphPad Software, San Diego, CA, USA) or SAS (Version 9.2, SAS Institute Inc., Cary, NC, USA) software.

Results
=======

Validation of a primary antibody against *β*V-tubulin for IHC
-------------------------------------------------------------

We used transgenically expressed murine *β*V-tubulin in HEK293T cells as positive control for the validation of several primary antibodies. To positively control for transgene expression, we applied HA-tagged *β*I-/*β*III-/*β*V-tubulin expression plasmids. Transfection efficacies in HEK293T cells ranged from 50 to 80% ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). Immunoblotting and IHC with an anti-HA primary antibody demonstrated successful transgene expression ([Supplementary Figures 1C and 2A--D](#sup1){ref-type="supplementary-material"}). Specific expression of *β*III-tubulin was confirmed using an anti-*β*III-tubulin antibody ([Supplementary Figures 2E--H](#sup1){ref-type="supplementary-material"}). Low expression of *β*V-tubulin was found in all cells, but overexpression of *β*V-tubulin was only seen in cells transfected with pTOP HAbV ([Supplementary Figures 2I--L](#sup1){ref-type="supplementary-material"}).

Immunohistochemistry was tested in a brain metastasis from a squamous cell carcinoma of the lung that was surrounded by a regular cortex with both neurons and glia cells ([Supplementary Figures 3A--C](#sup1){ref-type="supplementary-material"}). Neurons stained strongly ([Supplementary Figure 3B](#sup1){ref-type="supplementary-material"}), if the anti-*β*III-tubulin antibody was used, whereas glia and squamous cell carcinoma cells stained negatively. In contrast, *β*V-tubulin expression was detected almost exclusively in glia and tumour cells ([Supplementary Figure 3C](#sup1){ref-type="supplementary-material"}). Furthermore, in some tumour samples we observed an inversely proportional expression tubulin pattern (low *β*III/high *β*V) ([Supplementary Figures 3G--I](#sup1){ref-type="supplementary-material"}).

Association between *β*III-/*β*V-tubulin expression and clinicopathological data
--------------------------------------------------------------------------------

Cytoplasmatic expression of *β*III- and *β*V-tubulin in tumour cells was assessed by IHC and quantitated. Examples of different expression levels of *β*III- or *β*V-tubulin are depicted in [Figure 2](#fig2){ref-type="fig"}. Median *H*-scores were 110 (range: 0--290) for *β*III-tubulin, and 160 (range: 0--290) for *β*V-tubulin ([Supplementary Figure 4A](#sup1){ref-type="supplementary-material"}). At univariate analyses, no significant association between *β*III-tubulin expression and age, gender, primary tumour location, histological grade or subtype, or IASLC stage was found ([Table 2](#tbl2){ref-type="table"}). Furthermore, no correlation was observed between *β*V-tubulin expression and age, gender, primary tumour location, or histological grade ([Table 2](#tbl2){ref-type="table"}). A borderline significant association between histological subtypes and *β*V-tubulin expression was seen (*P*~KW~=0.0704). Squamous cell carcinomas expressed significantly higher *β*V-tubulin levels as compared with non-squamous cell carcinomas (mean *H-*score of 178±11, median 187.5 *vs* mean 141±9, median 150; *P*=0.0271). Furthermore, an association between clinicopathological stage and *β*V-tubulin expression was observed (*P*~KW~=0.0097), if IASLC stages IIIA, IIIB, and IV were compared. Stage III was associated with higher expression levels of *β*V-tubulin (mean *H-*score of 163±8, median 172.5) compared with stage IV (mean *H-*score of 99±18, median 105; *P*=0.0030).

Intratumoural correlation of *β*III- or *β*V-tubulin expression
---------------------------------------------------------------

In the entire cohort of patients a weak, but statistically significant correlation between *β*III- and *β*V-tubulin expression was seen (*r*=0.3561, *P*=0.0036; [Supplementary Figure 4B](#sup1){ref-type="supplementary-material"}). Further, we tested whether gender might influence the intratumoural *β*III-/*β*V-tubulin-correlation. We observed a weak, but significant, correlation in males (*r*=0.3081, *P*=0.0419; [Supplementary Figure 4D](#sup1){ref-type="supplementary-material"}), but not in females.

Association of *β*III- or *β*V-tubulin expression with response to induction chemotherapy
-----------------------------------------------------------------------------------------

We discovered an association between high *β*V-tubulin expression ([Table 3](#tbl3){ref-type="table"}) and improved OR (mean *H-*score of 163±9, median 172.5 for CR+PR *vs* 121±13, median 120 for SD+PD, *P*=0.0104). Similarly, high *β*V-tubulin levels were associated with better disease control (DC) (mean *H-*score of 158±8, median 170 for CR+PR+SD *vs* 91±22, median 100 for PD, *P*=0.0081). There were no significant associations between *β*III-tubulin expression and OR or DC to induction chemotherapy ([Table 3](#tbl3){ref-type="table"}). Neither *β*III- nor *β*V-tubulin levels were associated with OR or DC to radiochemotherapy (data not shown).

As we observed a significant association between high *β*V-tubulin protein levels and OR or DC, we calculated ROC curves revealing area under-the-curve (AUC) values of 0.7037 and 0.8091 for OR and DC, respectively. Therefore, we further estimated the sensitivity, specificity, positive and negative predictive value for *β*V-tubulin protein levels and OR, which were 74, 57, 54, and 84% by using a cutoff value of 167.5, respectively ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Using a cutoff value of 135 for *β*V-tubulin protein levels and DC, the values were 86, 66, 71, and 92% for sensitivity, specificity, positive and negative predictive value, respectively.

Association between *β*III- or *β*V-tubulin expression and survival
-------------------------------------------------------------------

Assessing the impact of tumour stages IIIA, IIIB, and IV on survival, we found a significant (*P⩽*0.001) association of tumour stage with PFS (median PFS stage IIIA: 19.2 months; IIIB: 15.2 months; and IV: 6.1 months). A borderline significant association of tumour stage and OS was observed (*P*=0.0761; median OS stage IIIA: ⩾36.1 months; IIIB: 59.3 months; and IV: 29.4 months).

At univariate analyses, *β*III-tubulin expression was associated with OS, but not with PFS ([Figures 3A and B](#fig3){ref-type="fig"}). Using the median *H-*scores as cutoff value, we found an association between favourable OS ([Figure 3B](#fig3){ref-type="fig"}) and low *β*III-tubulin protein expression (median OS 68.0 months *vs* 25.9 months in low *vs* high *β*III-tubulin expressors; HR: 0.328, 95% CI: 0.131 to 0.821; *P*=0.0127). High *β*V-tubulin expression was associated with prolonged PFS (median PFS 19.2 months *vs* 9.4 months for high *vs* low *β*V-tubulin expressors; HR: 1.899, 95% CI: 1.048--3.439; *P*=0.0315), but not with OS ([Figures 3C and D](#fig3){ref-type="fig"}). The association between OS and *β*III-tubulin expression remained significant when adjusting for histology (HR for 30 units of decrement or increment in *β*III-tubulin: 1.348 (95% CI: 1.106--1.641), *P*~COX~=0.0028) or both histology and *β*V-tubulin (HR for 30 units of decrement or increment in *β*III-tubulin: 1.411 (95% CI: 1.153--1.734), *P*~COX~=0.0009). Interaction terms where included as well, but they turned out nonsignificant that may also be due to small sample size. The same was true for the association between *β*V-tubulin and PFS observed at univariate analysis, which remained significant, when adjusting for histology (HR for 30 units of decrement or increment in *β*V-tubulin: 0.798 (95% CI: 0.677--0.938), *P*~COX~=0.0053). However, significance was lost when adjusting for histology and *β*III-tubulin expression (HR for 30 units of decrement or increment in *β*V-tubulin: 0.864 (95% CI: 0.690--1.081), *P*~COX~=0.1938). Furthermore, a significant interaction between histology and *β*III-tubulin expression was observed in Cox regression modelling PFS. Computing HRs for PFS and *β*III-tubulin in histologic subgroups revealed an HR for an decrease or increase of 30 units in *β*III-tubulin was 1.244 (95% CI: 1.012--1.535, *P*~COX~=0.039) for adenocarcinomas, HR was 0.803 (95% CI: 0.591--1.087, *P*~COX~=0.1569) for squamous cell carcinomas, and HR was 0.930 (95% CI: 0.644--1.310, *P*~COX~=0.6847) for all other histological subtypes.

Association between combined *β*III- or *β*V-tubulin expression and survival
----------------------------------------------------------------------------

Patients were categorised in four groups according to *β*III-/*β*V-tubulin expression: low *β*III/low *β*V, low *β*III/high *β*V, high *β*III/low *β*V, and high *β*III/high *β*V ([Figures 3E and F](#fig3){ref-type="fig"}). Analyses of PFS and OS revealed significant differences between 'low *β*III/high *β*V-tubulin expressors\' and 'high *β*III/low *β*V-tubulin expressors\' in PFS (*P*=0.0472) and OS (*P*=0.0012). Furthermore, patients with tumours expressing low *β*III- and high *β*V-tubulin levels had the longest OS (43.3 months), whereas patients whose tumours expressed high *β*III- and low *β*V-tubulin levels had the shortest OS (16.7 months).

Discussion
==========

Current medical treatment of advanced NSCLC patients still largely relies on classical cytotoxic agents. Tubulin-binding agents such as taxanes and *Vinca* alkaloids are effective as combination partners of platinum compounds, as well as in palliative monotherapy of relapsing or comorbid patients ([@bib13]). Moreover, TBAs are used as radiosensitisers in concurrent radiochemotherapy protocols ([@bib1]). Several agents that have recently been introduced into treatment of metastatic NSCLC are selected based on established biomarkers. Key examples are 'non-squamous\' histology for bevacizumab and pemetrexed, somatic *EGFR* mutations for erlotinib and gefitinib, and most recently *ALK* translocations for crizotinib ([@bib13]). In contrast, the selection of TBAs is still entirely based on clinical considerations. Although TBAs have clearly established efficacy in NSCLC, they are also associated with considerable toxicities including hematotoxicity, neurotoxicity, mucositis and alopecia. Hence, the definition of biomarkers for guidance of therapeutic application of TBAs would be of high clinical relevance.

Therefore, we have rationally selected immunohistochemically detectable intratumoural expression of *β*-tubulin isotypes for an association study with clinical outcome in a cohort of locally advanced and oligometastatic NSCLC patients. We focused on *β*-tubulins as they were implied in resistance to taxanes in various cancer cells ([@bib27]). Moreover, the level of *β*III-tubulin expression was reported to correlate with OR and PFS in retrospective analyses of NSCLC patients treated with paclitaxel-based regimens. As these studies did not provide conclusive results ([@bib29]; [@bib10]; [@bib30]; [@bib26]; [@bib2]; [@bib21]; [@bib35]; [@bib22]), we reasoned that combined expression analysis of the structurally similar isotypes *β*III- and *β*V-tubulin might provide a more comprehensive picture. At the initiation of our study an anti-*β*III-tubulin antibody, but no anti-*β*V-tubulin antibody was available for IHC of formalin-fixed paraffin-embedded tumour samples. Accordingly, we devised several positive and negative controls to establish and validate sensitivity and specificity of a commercially available anti-*β*V-tubulin antibody for this type of analysis.

Applying those two validated primary antibodies, we analysed tumour samples from 65 patients suffering from stage III or oligometastatic stage IV NSCLC. Despite being moderately sized, patients were treated uniformly with paclitaxel-based induction chemotherapy and vinorelbine-based radiochemotherapy, which enabled a meaningful analysis of the clinical interaction of *β*-tubulin expression and clinical outcome. However, a subgroup of 40 patients underwent surgery, whereas the remaining patients received a final boost of radiochemotherapy. We were able to observe for the first time that high expression of *β*V-tubulin was significantly associated with improved OR after paclitaxel-based induction chemotherapy and prolonged PFS. In keeping with previous reports also including perioperatively treated patients, an association of low *β*III-tubulin expression with improved OS ([@bib30]; [@bib26]; [@bib35]; [@bib22]) was found in our cohort, but not with OR ([@bib10]; [@bib1]) or PFS ([@bib29]; [@bib1]; [@bib21]). Although high expression of *β*V-tubulin was associated with squamous cell carcinomas, the positive correlation with PFS was maintained when adjusting for histology at regression analysis. Interestingly, *β*III- or *β*V-tubulin staining failed to correlate with OR to vinorelbine-based concurrent radiochemotherapy. Within the limitations of the size of our cohort, we suggest that a potential predictive value of *β*V-tubulin expression either is confined to taxanes or is confounded when TBAs are concurrently administered with radiation.

Surprisingly, high *β*V-tubulin levels were associated with better OR and prolonged PFS, but not lower levels. *In vitro* studies reported that murine *β*V-tubulin increased tolerance for paclitaxel in human cancer cells ([@bib4]) and might confer paclitaxel resistance ([@bib5]). But human *β*V-tubulin binds paclitaxel with a higher affinity than murine *β*V-tubulin does ([@bib33]). Furthermore, microtubules in mammalian cells depleted of *β*V-tubulin are more stable than normal. These cells have a reduced mitotic progression and might be less sensitive for polymerising paclitaxel ([@bib6]). But cells with a high expression of *β*V-tubulin have very low levels of polymerised *β*V-tubulin ([@bib7]). Therefore, overexpression of human *β*V-tubulin might increase sensitivity to paclitaxel. Additionally, a highly regulated balance between *β*III- and *β*V-tubulin occurs in cells, and the combined expression of *β*III- and *β*V-tubulin may not exceed ∼20% of the total *β*-tubulin ([@bib33]) for normal cell function. As *β*III- and *β*V-tubulin are expressed in a complementary pattern at the protein level, human cancer cells expressing *β*V-tubulin at higher levels might suppress *β*III-tubulin expression and be more paclitaxel sensitive.

There are several limitations in our study. First, this is a retrospective study. Only patients with available pre-treatment tumour samples were included in our study. Second, as patients with high *β*V-tubulin expression achieved a better mean OR to induction chemotherapy (*P*=0.0104), this might have resulted in skewing of the application of surgical procedures towards that subgroup. Third, significant associations between PFS/OS and protein levels of *β*III-tubulin were recently found in pulmonary adenocarcinoma patients, but not in squamous cell carcinomas ([@bib34]). Gender also influences the *β*III-/*β*V-tubulin ability to predict poor outcome in colorectal cancer ([@bib25]). But the patient number in our study was too low to perform meaningful subgroup analyses for adenocarcinoma or female patients. Fourth, although the induction chemotherapy and combined radiochemotherapy were uniform, the patient cohort is heterogenous. We will evaluate the predictive value of *β*III-/*β*V-tubulin expression within a prospective phase III clinical trial. This trial compares a final boost of radiochemotherapy to surgical resection as part of the multimodality treatment and is balanced for stage IIIA/B patients. Furthermore, we will explore the prognostic value of *β*III-/*β*V-tubulin expression in a cohort of IASLC stage I patients who were exclusively treated by surgery.

In conclusion, we have established semiquantitative immunohistochemical detection of *β*V-tubulin as a putative biomarker to predict outcome of advanced NSCLC patients following taxane-based chemotherapy. Combined analysis of *β*III- and *β*V-tubulin expression may provide more robust prognostic and/or predictive information. On the basis of these results and the validated suitability of our *β*V-tubulin staining protocol, prospective studies of these promising biomarkers in NSCLC patients treated with TBAs are warranted.
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![Flowchart showing the sequence of induction chemotherapy and combined radiochemotherapy, followed by surgical resection or a final boost of radiochemotherapy. Abbreviations: CTX: chemotherapy, hf: high frequency, RTX: radiotherapy.](bjc2012324f1){#fig1}

![Examples of IHC for the *β*III- or *β*V-tubulin isotypes in NSCLC samples showing different protein expressions of the regarding isotype. Upper panel: IHC with an antibody against *β*III-tubulin. (**A**) A negatively stained NSCLC sample (*H-*score of 0), (**B**) a moderately stained NSCLC sample (*H-*score of 180), and (**C**) a strongly stained NSCLC sample (*H-*score of 290); lower panel: IHC with an antibody against *β*V-tubulin. (**D**) A weakly stained NSCLC sample (*H-*score of 50), (**E**) a moderately stained NSCLC sample (*H-*score of 160), and (**F**) a strongly stained NSCLC sample (*H-*score of 290). Magnification: 1 : 100.](bjc2012324f2){#fig2}

![Associations between *β*III- or *β*V-tubulin protein expression and progression-free survival (PFS) or overall survival (OS). Associations between *β*III-tubulin expression and PFS (**A**) or OS (**B**), between *β*V-tubulin expression and PFS (**C**) or OS (**D**) or between combined expression of *β*III-/*β*V-tubulin and PFS (**E**) or OS (**F**). Patients were categorised by the median *H-*scores of *β*III-tubulin (110) or *β*V-tubulin (160).](bjc2012324f3){#fig3}

###### Clinicopathological data of investigated NSCLC patients

  **Characteristics**                                                    **Number of patients (%)**
  ---------------------------------------------------------------------- ----------------------------
  Number of patients (%)                                                 65 (100%)
  *Age*                                                                  
   Median age at diagnosis in years (range)                              53 (35--70)
  *Gender*                                                               
   Female                                                                21 (32%)
   Male                                                                  44 (68%)
  Side                                                                    
   Left                                                                  24 (37%)
   Right                                                                 41 (63%)
  *T stage*                                                              
   T1                                                                    3 (5%)
   T2                                                                    16 (25%)
   T3                                                                    16 (25%)
   T4                                                                    30 (46%)
  *N stage*                                                              
   N0                                                                    15 (23%)
   N1                                                                    5 (8%)
   N2                                                                    27 (42%)
   N3                                                                    18 (28%)
  *M stage*                                                              
   M0                                                                    55 (85%)
   M1                                                                    10 (15%)
  *IASLC stage (at diagnosis)*                                           
   I                                                                     2 (3%)
   II                                                                    1 (2%)
   III                                                                   52 (80%)
   IV                                                                    10 (15%)
  *Histologic subtype*                                                   
   Adenocarcinoma                                                        29 (45%)
   Squamous cell carcinoma                                               16 (25%)
   Large cell carcinoma                                                  6 (10%)
   Other tumours and mixed tumours                                       14 (22%)
  *Grading*                                                               
   G2                                                                    19 (29%)
   G3                                                                    42 (65%)
   G4                                                                    4 (6%)
  *Induction chemotherapy*                                               
   Cisplatin plus paclitaxel                                             63 (97%)
   Carboplatin plus paclitaxel                                           2 (3%)
   Median number of cycles (range)                                       3 (2--4)
   Median cumulative paclitaxel dose in mg (range)                       990 (560--1400)
  *Combined radiochemotherapy*                                           
   Cisplatin plus vinorelbine                                            50 (77%)
   Carboplatin plus vinorelbine                                          2 (3%)
   Cisplatin                                                             3 (5%)
   No concomitant chemotherapy                                           10 (15%)
   Median cumulative radiotherapy dose (in Gy; range)                    46 (30--71.6)
  *Response to induction chemotherapy*                                   
   CR                                                                    1 (2%)
   PR                                                                    45 (69%)
   SD                                                                    12 (18%)
   PD                                                                    7 (11%)
                                                                         
  *Response to induction chemotherapy* (only IASLC stage III patients)   52 (100%)
   CR                                                                    1 (2%)
   PR                                                                    38 (73%)
   SD                                                                    10 (19%)
   PD                                                                    3 (6%)
  *Response to induction chemotherapy (only IASLC stage IV patients)*    10 (100%)
   PR                                                                    6 (60%)
   PD                                                                    4 (40%)
  *Response to combined radiochemotherapy*                               
   CR                                                                    2 (3%)
   PR                                                                    31 (48%)
   SD                                                                    30 (46%)
   PD                                                                    2 (3%)
  *Survival*                                                             
   Median PFS in months (range)                                          14.1 (0.9--62.1)
   Median OS in months ( range)                                          59.3 (2.1--74.0)

Abbreviations: CR=complete remission; IASLC=International Association for the Study of Lung Cancer; NSCLC=non-small cell lung cancer; OS=overall survival; PD=progressive disease; PFS=progression-free survival; PR=partial remission; SD=stable diseasel. Note that percentages may not total 100 because of rounding.

###### Clinicopathological data and protein expression of the different *β*-tubulin isotypes

                             **(A)** ***β*****III-tubulin**   **(B)** ***β*****V-tubulin**                                                                                               
  -------------------------- -------------------------------- ----------------------------------------- ---------------- --------------------- ----------------------------------------- ----------------
                             **No. of patients**              ***H-*****score (mean±s.e.m., median)**                    **No. of patients**   ***H-*****score (mean±s.e.m., median)**    
  *Histology*                                                                                                                                                                            
   Adenocarcinoma            29                               122±13, 110                               *P*~KW~=0.6224   29                    137±12, 150                               *P*~KW~=0.0704
   Squamous cell carcinoma   16                               101±20, 105                                                16                    178±11, 187.5                              
   Other carcinomas          20                               121±16, 107.5                                              20                    147±15, 155                                
  *Histology*                                                                                                                                                                            
   Adenocarcinoma            29                               122±13, 110                               *P*=0.4838       29                    137±12, 150                               *P*=0.0960
   Other carcinomas          36                               112±12, 107.5                                              36                    161±10, 175                                
   Squamous cell carcinoma   16                               101±122, 105                              *P*=0.3524       16                    178±11, 187.5                             *P*=0.0271
   Other carcinomas          49                               122±10, 110                                                49                    141±9, 150                                 
  *Histological grade*                                                                                                                                                                   
   G2                        19                               132±17, 120                               *P*~KW~=0.4564   19                    162±15, 170                               *P*~KW~=0.5283
   G3                        44                               110±11, 102.5                                              44                    148±9, 155                                 
   G4                        2                                125±15, 125                                                2                     105±95, 105                                
  *Gender*                                                                                                                                                                               
   Female                    21                               129±18, 110                               *P*=0.2988       21                    151±14, 180                               *P*=0.4693
   Male                      44                               111±10, 105                                                44                    150±9, 157.5                               
  *Side*                                                                                                                                                                                 
   Left                      24                               120±15, 107.5                             *P*=0.8277       24                    147±14, 167.5                             *P*=0.8918
   Right                     41                               115±11, 110                                                41                    152±9, 155                                 
  *Stage*                                                                                                                                                                                
   IASLC IIIA                23                               99±15, 80                                 *P*~KW~=0.1348   23                    157±11, 170                               *P*~KW~=0.0097
   IASLC IIIB                29                               132±12, 120                                                29                    167±12, 180                                
   IASLC IV                  10                               119±29, 102.5                                              10                    99±18, 105                                 
  *Stage*                                                                                                                                                                                
   IASLC III                 52                               117±10, 110                               *P*=0.8631       52                    163±8, 172.5                              *P*=0.0030
   IASLC IV                  10                               119±29, 102.5                                              10                    99±18, 105                                 

Abbreviation: IASLC=International Association for the Study of Lung Cancer.

Association between (A) *β*III-tubulin or (B) *β*V-tubulin protein expression and clinicopathological data.

###### Associations between objective response (OR) or disease control (DC) during induction chemotherapy and (A) *β*III-tubulin or (B) *β*V-tubulin protein expression

                                      **(A)** ***β*****III-tubulin**   **(B)** ***β*****V-tubulin**                                                                                                  
  ----------------------------------- -------------------------------- ----------------------------------------- ------------------- --------------------- ----------------------------------------- -------------------
                                      **No. of patients**              ***H-*****score (mean±s.e.m., median)**   ***P*****-value**   **No. of patients**   ***H-*****score (mean±s.e.m., median)**   ***P*****-value**
  *Response to chemotherapy*                                                                                     0.7838                                                                              0.0104
   CR+PR                              46                               119±11, 110                                                   46                    163±9, 172.5                               
   SD+PD                              19                               111±15, 105                                                   19                    121±13, 120                                
                                                                                                                                                                                                      
  *Disease control to chemotherapy*                                                                              0.9746                                                                               
   CR+PR+SD                           58                               117±9, 110                                                    58                    158±8, 170                                0.0081
   PD                                 7                                114±29, 105                                                   7                     91±22, 100                                 

Abbreviations: CR=complete remission; PD=progressive disease; PR=partial remission; SD=stable disease.
